ENTX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

EN

Volume

551.26K

Next Earnings

November 13th

Loading chart

EN

ENTXEntera Bio Ltd. Ordinary Shares

ENTX

Pay with—

Available Balance0.00

EN

Mkt Cap

$481.5M

Volume

551.26K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth ConferenceEntera Bio Ltd. (NASDAQ: ENTX), a clinical-stage biopharmaceutical company developing oral peptide therapies, announced that CEO Miranda Toledano will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The company is advancing its lead candidate EB613 (oral PTH(1-34)) for osteoporosis treatment, which met primary and secondary endpoints in a Phase 2 study, with positive FDA feedback received on planned Phase 3 registrational studies.GlobeNewswire Inc. · Jul 31, 2026

Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to MarketEntera Bio received positive FDA feedback on its Phase 3 protocol for EB613, an oral osteoporosis tablet based on teriparatide. The FDA accepted the company's proposed single-study registrational strategy with approximately 750 postmenopausal women, using total hip bone mineral density at 12 months as the primary endpoint. Phase 3 is expected to initiate in late 2026 with topline results anticipated in H2 2028. The approval could represent the first oral anabolic osteoporosis treatment, addressing a market where injectable therapies have limited adoption despite high efficacy.GlobeNewswire Inc. · Jun 23, 2026

Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'— PLTR, RZLV, ENTX In Focus (UPDATED)U.S. stock futures rose on Monday following Friday's sharp sell-off, with major indices recovering from correction territory. President Trump suggested the U.S. could seize Iran's oil infrastructure while characterizing Iran's new leaders as 'very reasonable.' Markets are pricing in a 96.4% likelihood of unchanged Fed rates in April. Key movers include Palantir Technologies, Rezolve AI, and Entera Bio, while analyst Mohamed El-Erian warns of 'stagflationary winds' and economic headwinds ahead.Benzinga · Mar 30, 2026

Stock Market Today: S&P 500, Dow Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'—Palantir, Rezolve AI, Entera Bio In FocusU.S. stock futures rose on Monday following Friday's sharp sell-off, with major indices recovering from correction territory. President Trump's comments about Iran's new leaders being 'very reasonable' and potential oil agreements provided some market optimism. Key movers included Palantir (partnership expansion), Rezolve AI (raised revenue outlook), and Entera Bio (earnings miss). Analysts warn of 'stagflationary winds' and expect continued volatility ahead.Benzinga · Mar 30, 2026

OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26OPKO Health will report its financial results for Q4 and full year 2025 on February 26, 2026, followed by a conference call. The company has also expanded its partnership with Entera Bio to advance an oral long-acting PTH tablet for hypoparathyroidism treatment, marking the third successful program combining Entera's N-Tab platform with OPKO's protein chemistry capabilities.GlobeNewswire Inc. · Feb 12, 2026

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with HypoparathyroidismOPKO Health and Entera Bio have expanded their collaboration to develop the first oral long-acting PTH analog for hypoparathyroidism treatment, aiming to file an IND application in late 2026. The companies will maintain equal 50/50 ownership and cost-sharing for this program. Additionally, they are advancing oral oxyntomodulin (dual GLP-1/glucagon analog) with Phase 1 injectable data expected by end of 2026. Steve Rubin from OPKO has joined Entera's board.GlobeNewswire Inc. · Feb 4, 2026

Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare ConferenceEntera Bio's CEO will participate in the Evercore ISI Healthcare Conference, highlighting the company's progress in developing oral peptide therapies for conditions like osteoporosis and hypoparathyroidism.GlobeNewswire Inc. · Nov 18, 2025

Entera Bio Beats Q2 EPS EstimatesEntera Bio reported better-than-expected Q2 2025 earnings with a GAAP EPS of $0.06, secured FDA regulatory concurrence for EB613's Phase 3 trial, and maintained a strong cash position of $18.8 million to support operations through mid-Q3 2026.The Motley Fool · Aug 8, 2025

OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity SymposiumOPKO Health, Inc. and Entera Bio Ltd. announced that OPKO's ModeX Therapeutics division has formed a Scientific Advisory Board with leaders in immunology and oncology drug development. Additionally, OPKO and Entera's first-in-class dual GLP-1/Glucagon tablet candidate for obesity and metabolic disorders has been selected for presentation at the ENDO 2025 Annual Meeting.GlobeNewswire Inc. · Jun 25, 2025

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic DisordersOPKO Health and Entera Bio have entered into a collaboration agreement to advance an oral GLP-1/Glucagon dual agonist tablet into clinical trials for the treatment of obesity and metabolic disorders.GlobeNewswire Inc. · Mar 17, 2025

to start trading

EN

ENTXEntera Bio Ltd. Ordinary Shares

ENTX

Pay with—

Available Balance0.00

Your PositionYou don't own any ENTX yet.

Related Tickers

Earnings